Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 0.47
ENDP's Cash to Debt is ranked lower than
73% of the 712 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.35 vs. ENDP: 0.47 )
Ranked among companies with meaningful Cash to Debt only.
ENDP' s 10-Year Cash to Debt Range
Min: 0.07  Med: 1.62 Max: No Debt
Current: 0.47
Equity to Asset 0.38
ENDP's Equity to Asset is ranked lower than
81% of the 575 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.64 vs. ENDP: 0.38 )
Ranked among companies with meaningful Equity to Asset only.
ENDP' s 10-Year Equity to Asset Range
Min: 0.08  Med: 0.57 Max: 0.77
Current: 0.38
0.08
0.77
F-Score: 5
Z-Score: 1.32
M-Score: -2.27
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) -11.85
ENDP's Operating margin (%) is ranked lower than
81% of the 669 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.92 vs. ENDP: -11.85 )
Ranked among companies with meaningful Operating margin (%) only.
ENDP' s 10-Year Operating margin (%) Range
Min: -31.17  Med: 18.34 Max: 38.19
Current: -11.85
-31.17
38.19
Net-margin (%) -20.96
ENDP's Net-margin (%) is ranked lower than
84% of the 671 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.96 vs. ENDP: -20.96 )
Ranked among companies with meaningful Net-margin (%) only.
ENDP' s 10-Year Net-margin (%) Range
Min: -79.44  Med: 7.72 Max: 24.67
Current: -20.96
-79.44
24.67
ROE (%) -17.58
ENDP's ROE (%) is ranked lower than
80% of the 699 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.43 vs. ENDP: -17.58 )
Ranked among companies with meaningful ROE (%) only.
ENDP' s 10-Year ROE (%) Range
Min: -113.34  Med: 12.36 Max: 26.98
Current: -17.58
-113.34
26.98
ROA (%) -5.12
ENDP's ROA (%) is ranked lower than
76% of the 718 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.50 vs. ENDP: -5.12 )
Ranked among companies with meaningful ROA (%) only.
ENDP' s 10-Year ROA (%) Range
Min: -39.34  Med: 7.18 Max: 17.45
Current: -5.12
-39.34
17.45
ROC (Joel Greenblatt) (%) -32.26
ENDP's ROC (Joel Greenblatt) (%) is ranked lower than
79% of the 714 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 12.24 vs. ENDP: -32.26 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
ENDP' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -282.02  Med: 134.29 Max: 753.26
Current: -32.26
-282.02
753.26
Revenue Growth (3Y)(%) -4.60
ENDP's Revenue Growth (3Y)(%) is ranked lower than
79% of the 548 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.80 vs. ENDP: -4.60 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
ENDP' s 10-Year Revenue Growth (3Y)(%) Range
Min: -4.6  Med: 21.00 Max: 30.3
Current: -4.6
-4.6
30.3
» ENDP's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2014

ENDP Guru Trades in Q3 2014

Larry Robbins 5,658,326 sh (+43.96%)
John Griffin 676,600 sh (unchged)
Jana Partners Sold Out
Chuck Royce Sold Out
Louis Moore Bacon Sold Out
Mario Gabelli 22,900 sh (-4.18%)
Julian Robertson 20,300 sh (-10.96%)
John Griffin 5,698,528 sh (-16.38%)
Wallace Weitz 721,950 sh (-17.65%)
Joel Greenblatt 13,716 sh (-84.54%)
Paul Tudor Jones 19,281 sh (-89.13%)
» More
Q4 2014

ENDP Guru Trades in Q4 2014

RS Investment Management 351,943 sh (New)
Pioneer Investments 389,510 sh (New)
George Soros 1,748,729 sh (New)
Larry Robbins 6,851,326 sh (+21.08%)
Wallace Weitz 767,530 sh (+6.31%)
John Griffin 676,600 sh (unchged)
Julian Robertson Sold Out
Joel Greenblatt Sold Out
Paul Tudor Jones Sold Out
Mario Gabelli 19,900 sh (-13.10%)
John Griffin 4,409,000 sh (-22.63%)
» More
Q1 2015

ENDP Guru Trades in Q1 2015

Steve Mandel 3,270,117 sh (New)
Louis Moore Bacon 38,262 sh (New)
Dodge & Cox 2,560 sh (New)
Pioneer Investments 512,974 sh (+31.70%)
George Soros 2,217,176 sh (+26.79%)
John Griffin 4,939,000 sh (+12.02%)
RS Investment Management 356,720 sh (+1.36%)
Larry Robbins 6,845,883 sh (-0.08%)
Wallace Weitz 747,530 sh (-2.61%)
Mario Gabelli 14,650 sh (-26.38%)
» More
Q2 2015

ENDP Guru Trades in Q2 2015

Jim Simons 183,760 sh (New)
Diamond Hill Capital 12,850 sh (New)
Kyle Bass 24,779 sh (New)
Paul Tudor Jones 50,589 sh (New)
Joel Greenblatt 11,516 sh (New)
Louis Moore Bacon 685,413 sh (+1691.37%)
Larry Robbins 8,837,703 sh (+29.10%)
Wallace Weitz 961,135 sh (+28.57%)
Pioneer Investments 562,603 sh (+9.67%)
Steve Mandel 3,570,117 sh (+9.17%)
RS Investment Management 375,286 sh (+5.20%)
RS Investment Management 375,286 sh (+5.20%)
George Soros 2,299,781 sh (+3.73%)
Mario Gabelli 15,050 sh (+2.73%)
Dodge & Cox 2,560 sh (unchged)
John Griffin 4,200,000 sh (-14.96%)
» More
» Details

Insider Trades

Latest Guru Trades with ENDP

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Top Ranked Articles about Endo International PLC

Dodge & Cox Buys 2 New Stocks
Dodge & Cox was founded in 1930 and is a firm employing a long-term approach and strict price discipline. It has $250 billion in assets under management and returned 11.32% on average annually over the past 20 years, compared to 9.39% for the S&P 500. Read more...
Larry Robbins Lives Up to Reputation for Investing in Healthcare Sector
During the campaigns in the recently concluded midterm elections, incumbent Democrats were reluctant to speak of Obamacare, almost as hesitant as they were to be seen with the president, on the campaign trail. Read more...

Ratios

vs
industry
vs
history
Forward P/E 14.10
ENDP's Forward P/E is ranked higher than
73% of the 232 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 23.47 vs. ENDP: 14.10 )
Ranked among companies with meaningful Forward P/E only.
N/A
P/B 2.53
ENDP's P/B is ranked higher than
56% of the 639 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.05 vs. ENDP: 2.53 )
Ranked among companies with meaningful P/B only.
ENDP' s 10-Year P/B Range
Min: 1.48  Med: 2.99 Max: 17.5
Current: 2.53
1.48
17.5
P/S 3.84
ENDP's P/S is ranked lower than
60% of the 664 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.08 vs. ENDP: 3.84 )
Ranked among companies with meaningful P/S only.
ENDP' s 10-Year P/S Range
Min: 1.03  Med: 2.84 Max: 6.1
Current: 3.84
1.03
6.1
PFCF 45.69
ENDP's PFCF is ranked lower than
57% of the 274 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 40.71 vs. ENDP: 45.69 )
Ranked among companies with meaningful PFCF only.
ENDP' s 10-Year PFCF Range
Min: 4.6  Med: 10.41 Max: 264.07
Current: 45.69
4.6
264.07
POCF 35.32
ENDP's POCF is ranked lower than
62% of the 393 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 27.63 vs. ENDP: 35.32 )
Ranked among companies with meaningful POCF only.
ENDP' s 10-Year POCF Range
Min: 3.96  Med: 9.98 Max: 90.18
Current: 35.32
3.96
90.18
Current Ratio 2.16
ENDP's Current Ratio is ranked lower than
53% of the 619 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.29 vs. ENDP: 2.16 )
Ranked among companies with meaningful Current Ratio only.
ENDP' s 10-Year Current Ratio Range
Min: 1.07  Med: 1.95 Max: 3.55
Current: 2.16
1.07
3.55
Quick Ratio 1.98
ENDP's Quick Ratio is ranked higher than
56% of the 618 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.68 vs. ENDP: 1.98 )
Ranked among companies with meaningful Quick Ratio only.
ENDP' s 10-Year Quick Ratio Range
Min: 0.91  Med: 1.78 Max: 3.34
Current: 1.98
0.91
3.34
Days Inventory 118.53
ENDP's Days Inventory is ranked lower than
54% of the 634 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 111.99 vs. ENDP: 118.53 )
Ranked among companies with meaningful Days Inventory only.
ENDP' s 10-Year Days Inventory Range
Min: 66.62  Med: 110.31 Max: 157.75
Current: 118.53
66.62
157.75
Days Sales Outstanding 159.69
ENDP's Days Sales Outstanding is ranked lower than
89% of the 601 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 70.80 vs. ENDP: 159.69 )
Ranked among companies with meaningful Days Sales Outstanding only.
ENDP' s 10-Year Days Sales Outstanding Range
Min: 62.07  Med: 105.28 Max: 164.01
Current: 159.69
62.07
164.01

Valuation & Return

vs
industry
vs
history
Price/Projected FCF 1.66
ENDP's Price/Projected FCF is ranked higher than
68% of the 319 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.70 vs. ENDP: 1.66 )
Ranked among companies with meaningful Price/Projected FCF only.
ENDP' s 10-Year Price/Projected FCF Range
Min: 0.4  Med: 0.73 Max: 2.21
Current: 1.66
0.4
2.21
Price/Median PS Value 1.45
ENDP's Price/Median PS Value is ranked lower than
65% of the 597 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.26 vs. ENDP: 1.45 )
Ranked among companies with meaningful Price/Median PS Value only.
ENDP' s 10-Year Price/Median PS Value Range
Min: 0.39  Med: 1.13 Max: 2.94
Current: 1.45
0.39
2.94
Price/Peter Lynch Fair Value 65.18
ENDP's Price/Peter Lynch Fair Value is ranked lower than
559% of the 159 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.72 vs. ENDP: 65.18 )
Ranked among companies with meaningful Price/Peter Lynch Fair Value only.
ENDP' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.38  Med: 0.76 Max: 27.58
Current: 65.18
0.38
27.58
Earnings Yield (Greenblatt) (%) -1.90
ENDP's Earnings Yield (Greenblatt) (%) is ranked lower than
76% of the 700 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.40 vs. ENDP: -1.90 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
ENDP' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: -1.91  Med: 9.00 Max: 25.4
Current: -1.9
-1.91
25.4
Forward Rate of Return (Yacktman) (%) 18.50
ENDP's Forward Rate of Return (Yacktman) (%) is ranked higher than
72% of the 320 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.88 vs. ENDP: 18.50 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
ENDP' s 10-Year Forward Rate of Return (Yacktman) (%) Range
Min: 3.3  Med: 30.00 Max: 63.3
Current: 18.5
3.3
63.3

Analyst Estimate

Dec15 Dec16 Dec17 Dec18
Revenue(Mil) 3,051 3,807 4,011 4,024
EPS($) 4.49 5.31 6.18 6.88
EPS without NRI($) 4.49 5.31 6.18 6.88

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:TKPYY, TEVA, AGN, FRX, MRX » details
Traded in other countries:EO7.Germany, ENL.Canada,
Endo International PLC was incorporated in Ireland on October 31, 2013. It is a specialty healthcare company engaged in developing, manufacturing, marketing and distributing branded pharmaceutical and generic products as well as medical devices. Its current portfolio is associated with a set of therapeutic areas including, Allergy Immunotherapy, Central Precocious Puberty, Dermatology, Insomnia, Pain, Pelvic Health, Urology and Women's Health.
» More Articles for ENDP

Headlines

Articles On GuruFocus.com
Mandel’s Lone Pine Takes Stake in Growing Horizon Pharma Jul 28 2015 
John Griffin Shows Stake in Trendy Fitbit Inc. Jun 30 2015 
Dodge & Cox Buys 2 New Stocks Jun 10 2015 
Endo International Acquires Par Pharmaceuticals For $8 Billion May 21 2015 
Endo International Posts Upbeat Q1 Results May 13 2015 
Endo Pharmaceuticals Posts A Solid Q1 Earnings Report May 12 2015 
Weitz Value Fund First Quarter 2015 Commentary Apr 20 2015 
Weekly Insider Sells Highlight: ANTM, ENDP, QVCA, TOL Apr 12 2015 
Valeant Finally Bags Salix for $11 Billion Apr 06 2015 
This Week’s Pharma Highlights Mar 19 2015 

More From Other Websites
Endo International: Uncertain Growth Beyond 2017? Sep 01 2015
Growth Uncertainty For Endo Continues Through 2017 Sep 01 2015
Endo Health downgraded by Morgan Stanley Sep 01 2015
Drug launch in Japan to trigger $20M payment to Endo Aug 31 2015
Endo Pharmaceuticals Announces XIAFLEX® for Dupuytren's Contracture Formal Pricing in Japan;... Aug 31 2015
Endo Pharmaceuticals Announces XIAFLEX® for Dupuytren's Contracture Formal Pricing in Japan;... Aug 31 2015
Endo Pharmaceuticals Announces XIAFLEX® for Dupuytren's Contracture Formal Pricing in Japan;... Aug 31 2015
Mid-cap Healthcare Stocks The Smart Money Is Crazy About Aug 29 2015
Drug Deal Valuations Soar as Par Gains 300%: Real M&A Aug 26 2015
Pharmaceutical Stocks Affect the iShares NASDAQ Biotechnology ETF Aug 25 2015
ENDO INTERNATIONAL PLC Financials Aug 20 2015
Endo Gets Favorable Ruling Related to Opana ER in U.S. Aug 17 2015
Court ruling upholds Endo pain product patents Aug 17 2015
Top Mid-Cap Stocks Smart Money Love: Cheniere Energy Inc. (LNG), Liberty Interactive Corporation... Aug 17 2015
Endo Wins Order Blocking Generic of Opana ER Until 2023 Aug 14 2015
Endo Announces U.S. District Court Ruling Upholding OPANA® ER Intellectual Property Aug 14 2015
Endo Announces U.S. District Court Ruling Upholding OPANA® ER Intellectual Property Aug 14 2015
Endo Announces U.S. District Court Ruling Upholding OPANA® ER Intellectual Property Aug 14 2015
Endo Announces Appearance at Canaccord Genuity 35th Annual Growth Conference Aug 11 2015
Endo Announces Appearance at Canaccord Genuity 35th Annual Growth Conference Aug 11 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK